Bio4Dreams’ first partial exit from ChemiCare

6 September 2024

Corporate

Portfolio

/

Bio4Dreams has completed its first partial exit from ChemiCare, achieving a 9.5x return on investment.

In February 2024, Bio4Dreams completed its first partial exit from the innovative SME ChemiCare. The exit generated a 9.5x return on investment and was finalized as part of a new capital increase of 500 thousand euros, set to conclude at the end of september. This increase has already seen the entry of Bridge4Pharma into the company’s capital.

ChemiCare develops modulators of the Store-Operated Calcium Entry (SOCE) as a therapy for calcium-related diseases; it was incubated and invested in by Bio4Dreams in 2021 and has raised over 1 million euros since its establishment, considering both capital increases and grants received.

Since 2022, the EMA has granted two orphan drug designations to ChemiCare’s CIC-39 molecule for the treatment of a group of rare genetic diseases related to calcium alterations and for Duchenne muscular dystrophy.

📈 See the investors page.

Altri aggiornamenti

11 Oct 24

Corporate

FDA grants orphan drug designation to ChemiCare’s drug candidate

Bio4Dreams’ first partial exit from ChemiCare

6 September 2024

Corporate

Portfolio

/

Bio4Dreams has completed its first partial exit from ChemiCare, achieving a 9.5x return on investment.

In February 2024, Bio4Dreams completed its first partial exit from the innovative SME ChemiCare. The exit generated a 9.5x return on investment and was finalized as part of a new capital increase of 500 thousand euros, set to conclude at the end of september. This increase has already seen the entry of Bridge4Pharma into the company’s capital.

ChemiCare develops modulators of the Store-Operated Calcium Entry (SOCE) as a therapy for calcium-related diseases; it was incubated and invested in by Bio4Dreams in 2021 and has raised over 1 million euros since its establishment, considering both capital increases and grants received.

Since 2022, the EMA has granted two orphan drug designations to ChemiCare’s CIC-39 molecule for the treatment of a group of rare genetic diseases related to calcium alterations and for Duchenne muscular dystrophy.

📈 See the investors page.

Altri aggiornamenti

11 Oct 24

Corporate

Bio4Dreams among the partner of Startup Breeze 2024

8 Oct 24

Corporate

Bio4Dreams joins CEBR, expanding its network across Europe

4 Oct 24

Portfolio

BiomimX: expands with new spaces at Bio4Dreams HQ

3 Oct 24

Corporate

Bio4Dreams partner of Unipa’s new hub for tech transfer

27 Sep 24

Portfolio

FDA grants orphan drug designation to ChemiCare’s drug candidate

Bio4Dreams’ first partial exit from ChemiCare

6 September 2024

Corporate

Portfolio

/

Bio4Dreams has completed its first partial exit from ChemiCare, achieving a 9.5x return on investment.

In February 2024, Bio4Dreams completed its first partial exit from the innovative SME ChemiCare. The exit generated a 9.5x return on investment and was finalized as part of a new capital increase of 500 thousand euros, set to conclude at the end of september. This increase has already seen the entry of Bridge4Pharma into the company’s capital.

ChemiCare develops modulators of the Store-Operated Calcium Entry (SOCE) as a therapy for calcium-related diseases; it was incubated and invested in by Bio4Dreams in 2021 and has raised over 1 million euros since its establishment, considering both capital increases and grants received.

Since 2022, the EMA has granted two orphan drug designations to ChemiCare’s CIC-39 molecule for the treatment of a group of rare genetic diseases related to calcium alterations and for Duchenne muscular dystrophy.

📈 See the investors page.

Altri aggiornamenti

11 Oct 24

Corporate

Bio4Dreams among the partner of Startup Breeze 2024

8 Oct 24

Corporate

Bio4Dreams joins CEBR, expanding its network across Europe

4 Oct 24

Portfolio

BiomimX: expands with new spaces at Bio4Dreams HQ

3 Oct 24

Corporate

Bio4Dreams partner of Unipa’s new hub for tech transfer

27 Sep 24

Portfolio

FDA grants orphan drug designation to ChemiCare’s drug candidate

Bio4Dreams’ first partial exit from ChemiCare

6 September 2024

Corporate

Portfolio

/

Bio4Dreams has completed its first partial exit from ChemiCare, achieving a 9.5x return on investment.

In February 2024, Bio4Dreams completed its first partial exit from the innovative SME ChemiCare. The exit generated a 9.5x return on investment and was finalized as part of a new capital increase of 500 thousand euros, set to conclude at the end of september. This increase has already seen the entry of Bridge4Pharma into the company’s capital.

ChemiCare develops modulators of the Store-Operated Calcium Entry (SOCE) as a therapy for calcium-related diseases; it was incubated and invested in by Bio4Dreams in 2021 and has raised over 1 million euros since its establishment, considering both capital increases and grants received.

Since 2022, the EMA has granted two orphan drug designations to ChemiCare’s CIC-39 molecule for the treatment of a group of rare genetic diseases related to calcium alterations and for Duchenne muscular dystrophy.

📈 See the investors page.